AVITA MED LTD/S (OTCMKTS: AVMXY) is one of 128 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare AVITA MED LTD/S to related companies based on the strength of its analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings.
Valuation & Earnings
This table compares AVITA MED LTD/S and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|AVITA MED LTD/S||$5.51 million||-$24.75 million||-19.15|
|AVITA MED LTD/S Competitors||$793.72 million||$158.02 million||5.84|
Institutional and Insider Ownership
0.0% of AVITA MED LTD/S shares are held by institutional investors. Comparatively, 51.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 18.5% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Risk & Volatility
AVITA MED LTD/S has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, AVITA MED LTD/S’s competitors have a beta of 1.65, meaning that their average share price is 65% more volatile than the S&P 500.
This table compares AVITA MED LTD/S and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AVITA MED LTD/S||N/A||N/A||N/A|
|AVITA MED LTD/S Competitors||-4,420.38%||-83.08%||-36.03%|
This is a summary of recent ratings and target prices for AVITA MED LTD/S and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AVITA MED LTD/S||0||0||1||0||3.00|
|AVITA MED LTD/S Competitors||1080||3280||6857||303||2.55|
AVITA MED LTD/S currently has a consensus target price of $10.00, indicating a potential upside of 33.87%. As a group, “Biological products, except diagnostic” companies have a potential upside of 48.87%. Given AVITA MED LTD/S’s competitors higher possible upside, analysts clearly believe AVITA MED LTD/S has less favorable growth aspects than its competitors.
AVITA MED LTD/S competitors beat AVITA MED LTD/S on 8 of the 13 factors compared.
AVITA MED LTD/S Company Profile
Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company's patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin. Its lead product, RECELL System, is used in the treatment of various skin defects, such as burns and plastic reconstructive procedures. The company also offers ReGenerCell for chronic wounds and ReNovaCell for the restoration of pigmentation. Avita Medical Limited is based in Valencia, California.
Receive News & Ratings for AVITA MED LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA MED LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.